Search

Hutchison China MediTech Ltd ADR

Fechado

SetorSaúde

14.8 5.04

Visão Geral

Variação de preço das ações

24h

Atual

Mín

14.69

Máximo

15.2

Indicadores-chave

By Trading Economics

Rendimento

-8.9M

-8M

Vendas

3.7M

139M

P/E

Médio do Setor

132.7

51.78

Margem de lucro

-5.724

Funcionários

1,790

EBITDA

18M

4M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+20.38% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

394M

2.3B

Abertura anterior

9.76

Fecho anterior

14.8

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de nov. de 2026, 23:51 UTC

News

UBS maintains a Sell rating on Dropbox Inc and raises its price target to $26, contributing to the stock's after-market decline.

6 de nov. de 2026, 23:51 UTC

News

Viridian Therapeutics will host a conference call on November 9, 2026, to present data from its VRDN-008 phase 1 clinical trial and discuss development plans.

6 de nov. de 2026, 23:41 UTC

News

Citigroup reaffirms Buy rating on Cummins Inc and raises price target to $525, with shares advancing in after-market trading.

6 de nov. de 2026, 23:36 UTC

News

Ingredion Inc reported Q3 2026 net sales of $1.79 billion and net income of $142 million, while shares traded higher in after-market hours.

6 de nov. de 2026, 23:26 UTC

News

Citigroup maintains Neutral rating on HubSpot, lowering its price target to $230, reflecting ongoing assessment of the company's performance.

6 de nov. de 2026, 23:26 UTC

News

Citigroup maintains its Buy rating on Aptiv PLC and raises its price target to $68, contributing to a modest rebound in after-market trading.

6 de nov. de 2026, 23:16 UTC

News

UBS upgraded JinkoSolar Holding Co., Ltd. to Buy and set a price target of $17, reflecting a positive outlook on the company's performance.

6 de nov. de 2026, 23:12 UTC

News

JP Morgan maintains Overweight rating on Cloudflare, Inc. and raises price target to $375, a development published shortly before Friday's market close.

6 de nov. de 2026, 23:11 UTC

News

Truist Securities raises Insulet Corporation's price target to $160.00 from $153.00 while maintaining a Hold rating, as shares decline in after-market trading.

6 de nov. de 2026, 23:11 UTC

News

Lemonade Inc filed a mixed shelf registration statement for potential issuance of securities, contributing to its modest price increase in after-market trading.

6 de nov. de 2026, 23:11 UTC

News

Boston Scientific shares advanced in after-market trading, recovering from three sessions of declines, despite S&P Global Ratings revising its outlook to negative.

6 de nov. de 2026, 23:06 UTC

News

Pfizer Inc. shares traded modestly lower during after-market hours on Friday, continuing a downward trend that began shortly after the market closed.

6 de nov. de 2026, 23:06 UTC

Social Media
News

NVIDIA Corporation's shares advanced after a rebound in the technology sector, aligning with broader gains across Wall Street amid renewed interest in AI-related stocks.

6 de nov. de 2026, 23:06 UTC

News

NIO Inc. shares are trading lower in after-market hours as the CEO calls for national limits on electric vehicle weight in China, citing infrastructure concerns.

6 de nov. de 2026, 23:06 UTC

News

U.S. State Department approves potential $1.08 billion sale of UH-60M Blackhawk helicopters to Mexico, enhancing Lockheed Martin's position in the defense sector.

6 de nov. de 2026, 23:06 UTC

News

Citigroup maintains a Neutral rating on Wendy's Co and raises its price target to $8, reflecting the firm's assessment of the company's performance.

6 de nov. de 2026, 23:06 UTC

News

Citigroup maintains its Buy rating on Unity Software Inc. and raises the price target to $59, reflecting confidence in the company's growth prospects.

6 de nov. de 2026, 23:02 UTC

News

Hawaiian Electric Industries reports Q3 2026 net income of $35 million, boosted by $64 million in pre-tax gains, with revenue rising to $1.01 billion.

6 de nov. de 2026, 23:02 UTC

News
Correlated Moves

ON Semiconductor is trading higher in after-market hours, reaching its highest point since Friday's close, while ASE Technology has also advanced.

6 de nov. de 2026, 23:02 UTC

News
Social Media

Lam Research Corporation announced a $25 billion share buyback program and a quarterly dividend of $0.33, contributing to a significant increase in its stock price.

6 de nov. de 2026, 23:02 UTC

News

Airbnb reports Q3 revenue growth of 19% to $4.87 billion and EPS of $3.16, exceeding expectations; announces $12 billion buyback program and raises 2026 outlook.

6 de nov. de 2026, 23:02 UTC

News

A class action lawsuit has been filed against AppLovin Corporation by Kaplan Fox & Kilsheimer LLP, alleging misleading statements about its AI video tool development.

6 de nov. de 2026, 23:01 UTC

News

Medtronic PLC shares declined in after-market trading, continuing a trend of lower closes over the past three sessions, despite earlier gains in the session.

6 de nov. de 2026, 23:01 UTC

News

McDonald's faces a class-action lawsuit alleging mislabeling of McCafé beverages as “sugar free,” despite containing up to 18 grams of sugar.

6 de nov. de 2026, 22:41 UTC

News

Citigroup maintains Neutral rating on Westlake Corp and raises price target to $70, reflecting an updated assessment of the company's performance.

6 de nov. de 2026, 22:41 UTC

News

Parker-Hannifin Corporation will participate in the Robert W. Baird Global Industrial Conference on November 10, 2026, and has a market cap of $112.53 billion.

6 de nov. de 2026, 22:02 UTC

Macro Event
News
Correlated Moves

The USD/DKK exchange rate is modestly higher, following strong U.S. labor data showing a 165k increase in non-farm payrolls and a 4.1% unemployment rate.

6 de nov. de 2026, 22:02 UTC

Macro Event
News
Correlated Moves

The USD/CZK exchange rate is modestly higher, supported by strong U.S. labor market data, including a 165k increase in non-farm payrolls for October.

6 de nov. de 2026, 22:01 UTC

News

Harley-Davidson files for a mixed securities shelf, outlining potential issuance of various securities, though the offering size remains undisclosed.

6 de nov. de 2026, 21:13 UTC

News

Mueller Industries declares a fourth-quarter cash dividend of $0.175 per share, payable on December 18, with a record date of December 4.

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

20.38% parte superior

Previsão para 12 meses

Média 18.25 USD  20.38%

Máximo 18.5 USD

Mínimo 18 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

2

Comprar

0

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat